Seven-year safety and efficacy with velaglucerase alfa for treatment-naïve adult patients with type 1 Gaucher disease

about

Profile of eliglustat tartrate in the management of Gaucher disease A new framework for evaluating the health impacts of treatment for Gaucher disease type 1.

P2860

Q26774416-49F10F6A-6FE3-4A78-9F53-ECB341A57E00 Q37655469-1F5B4DCA-AF95-4DD9-9E7C-A4D315A12665

P2860

Seven-year safety and efficacy with velaglucerase alfa for treatment-naïve adult patients with type 1 Gaucher disease

Item

http://www.wikidata.org/entity/Q37275637

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 28 May 2015

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Seven-year safety and efficacy ...... ts with type 1 Gaucher disease

@en

Seven-year safety and efficacy ...... s with type 1 Gaucher disease.

@nl

type

Item

label

Seven-year safety and efficacy ...... ts with type 1 Gaucher disease

@en

Seven-year safety and efficacy ...... s with type 1 Gaucher disease.

@nl

prefLabel

Seven-year safety and efficacy ...... ts with type 1 Gaucher disease

@en

Seven-year safety and efficacy ...... s with type 1 Gaucher disease.

@nl

P1476

Seven-year safety and efficacy ...... ts with type 1 Gaucher disease

@en

P2093

Ari Zimran

http://www.w3.org/2001/XMLSchema#string

Carol Ogg

http://www.w3.org/2001/XMLSchema#string

Deborah Elstein

http://www.w3.org/2001/XMLSchema#string

Eric Crombez

http://www.w3.org/2001/XMLSchema#string

Gabriel M Cohn

http://www.w3.org/2001/XMLSchema#string

Nan Wang

http://www.w3.org/2001/XMLSchema#string

P2860

Characterization of gene-activated human acid- -glucosidase: Crystal structure, glycan composition, and internalization into macrophages

Multi-ethnic reference values for spirometry for the 3-95-yr age range: the global lung function 2012 equations

Therapeutic goals in the treatment of Gaucher disease.

Early achievement and maintenance of the therapeutic goals using velaglucerase alfa in type 1 Gaucher disease.

How to approach thrombocytopenia.

Enzyme replacement therapy with velaglucerase alfa in Gaucher disease: Results from a randomized, double-blind, multinational, Phase 3 study.

Velaglucerase alfa enzyme replacement therapy compared with imiglucerase in patients with Gaucher disease.

Outcome of pregnancies in women receiving velaglucerase alfa for Gaucher disease.

A multicenter open-label treatment protocol (HGT-GCB-058) of velaglucerase alfa enzyme replacement therapy in patients with Gaucher disease type 1: safety and tolerability

Limitations of drug registries to evaluate orphan medicinal products for the treatment of lysosomal storage disorders.

P304

577-583

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/AJH.24040

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2015-05-28T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

275359793

http://www.w3.org/2001/XMLSchema#string

P698

25903392

http://www.w3.org/2001/XMLSchema#string

P932

5033020

http://www.w3.org/2001/XMLSchema#string

Seven-year safety and efficacy with velaglucerase alfa for treatment-naïve adult patients with type 1 Gaucher disease

about

P2860

P2860

Seven-year safety and efficacy with velaglucerase alfa for treatment-naïve adult patients with type 1 Gaucher disease

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P5875

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P5875

P698

P932